
Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

Here for More.



1st FDA-approved treatment for adults with SLE in over a decade.

SAPHNELO is for adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are on other lupus medicines. Not for severe active lupus nephritis or central nervous system lupus.

IMPORTANT SAFETY INFORMATION

- **Do not use SAPHNELO** if you are allergic to anifrolumab-fnia or to any of the ingredients
- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you:**
  - think you have an infection or have an infection that keeps coming back

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

Why SAPHNELO?

In clinical studies of adult patients with moderate to severe SLE and receiving other lupus medicines, SAPHNELO:

Reduced disease activity
across different parts of the body and organs that lupus can affect.*,†

Early responses observed
Patients experienced changes in their lupus symptoms—some within weeks after starting treatment.*,†

Reduced oral steroid use
SAPHNELO is the only FDA-approved biologic for adults with moderate to severe lupus that's shown to significantly lower steroid use.*,‡,§

Reduced lupus flares*,‖



Results may vary. Always discuss your treatment plan with your healthcare provider.

*Compared to other lupus medicines alone.

†Disease activity reduction at end of treatment was statistically significant in 2 of the 3 studies.

‡A reduction of steroid use was seen but was not statistically significant in 2 of the 3 studies.

§In some patients using oral steroids ≥10 mg per day at study start, oral steroid dose was reduced to ≤7.5 mg per day.

‖Results were not statistically significant in the 3 studies.

IMPORTANT SAFETY INFORMATION (cont'd)

- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you: (cont'd)**
  - are scheduled to receive a vaccination or if you think you may need a vaccination. You should not receive live vaccines during treatment with SAPHNELO
  - have or have had cancer
  - are receiving other biologic medicines or monoclonal antibodies

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.



Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

How SAPHNELO works

Type 1 interferon (IFN-1) plays a key role in lupus. SAPHNELO blocks IFN-1 activity.

IFN-1

are tiny messengers in your body that send signals to several types of immune cells to activate the immune system when needed. In lupus, there are elevated levels of IFN-1, which can lead to an increase in IFN-1 activity and cause immune cells to attack your body.

Up to 80%

of people with active lupus have elevated levels of IFN-1 gene expression.

SAPHNELO

blocks the activity of IFN-1 by working across both parts of your immune system.

1st

SAPHNELO is the first and only FDA-approved treatment for adults with moderate to severe SLE that works by blocking IFN-1 activity.

IMPORTANT SAFETY INFORMATION (cont'd)

- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you: (cont'd)**
  - are pregnant or plan to become pregnant. It is not known if SAPHNELO will harm your unborn baby. Tell your healthcare provider if you are, might be, or plan to become pregnant during treatment with SAPHNELO
    - A pregnancy exposure registry monitors pregnancy outcomes in women exposed to SAPHNELO. You can find out more information about the registry by calling AstraZeneca at 1-877-693-9268
  - are breastfeeding or plan to breastfeed. It is not known if SAPHNELO passes into your breast milk

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

Starting SAPHNELO

SAPHNELO is a prescription medicine given by your healthcare provider through a needle placed in a vein (IV or intravenous infusion).

LOCATION

Your healthcare team will advise you on the location for treatment. It could be at your doctor's office, a hospital, or infusion center.

DOSING

SAPHNELO is usually given 1 time every 4 weeks.

DURATION

The infusion typically takes about 30 minutes to give you the full dose of SAPHNELO.

About **30 minutes** every **4 weeks**



IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works.

SAPHNELO may cause serious side effects, including:

- **Serious infections:** SAPHNELO can lower the ability of your immune system to fight infections. You may be at a higher risk of developing respiratory infections and shingles (herpes zoster) during treatment with SAPHNELO. Infections could be serious, leading to hospitalization or death

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Get the full Doctor Discussion Guide

download here

Or scan the QR code below.



Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

Ask your doctor about SAPHNELO

Here are some questions that you may find helpful to ask when talking with your doctor about SAPHNELO. Together, you can determine if SAPHNELO is right for you.

- ☐ **Is SAPHNELO different from other lupus treatments?**
- ☐ **What kind of results can I expect?**
- ☐ **When can I expect changes in my lupus symptoms?**
- ☐ **Will I need to stay on my other lupus medications?**
- ☐ **Will SAPHNELO help reduce my oral steroid use?**
- ☐ **What are the potential side effects of SAPHNELO?**

Any additional questions:

IMPORTANT SAFETY INFORMATION (cont'd)

SAPHNELO may cause serious side effects, including: (cont'd)

- **Allergic (hypersensitivity) reactions,** including anaphylaxis: Serious allergic reactions can happen during or after you get your SAPHNELO infusion. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of a serious allergic reaction:
  - swelling of your face, mouth and tongue
  - breathing problems
  - fainting, dizziness
  - feeling lightheaded (low blood pressure)

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

Support, designed with you in mind

SAPHNELO Supports is a program created with input from real patients. When you sign up, you'll have access to:

WELCOME KIT
An all-in-one box filled with details about starting SAPHNELO, including what to expect, helpful resources, and savings information

CARE COACHING
Can help you prepare yourself for treatment and get the most out of the resources available*

NURSE HELPLINE
If you have questions about SAPHNELO or available resources, AstraZeneca can help*

Scan the QR code or click here to enroll



Saving on SAPHNELO

If you are prescribed SAPHNELO and have commercial insurance, you may be able to get SAPHNELO ***for as little as $0***.†

Pay as little as $0†

To enroll into the SAPHNELO Patient Savings Program, please visit saphnelo.com or call 1-866-SAPHNELO (1-866-727-4635) for assistance.

Subject to eligibility and terms of use.

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

*Your AstraZeneca Care Coach cannot provide medical advice and can provide information about AstraZeneca medications only. Decisions regarding your health and treatment of your condition should be made with your own healthcare provider.

†The SAPHNELO Patient Savings Program is for commercially insured patients to cover patient out-of-pocket costs for SAPHNELO® (anifrolumab-fnia) and its infusion administration up to $16,500 per calendar year. Patients with commercial insurance where the health plan does NOT cover SAPHNELO may qualify for the Denied Patient Savings Program. Subject to eligibility and terms of use.

Patients must have commercial health insurance and a valid prescription for SAPHNELO. Patients who are enrolled in a state or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico. Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.

Other restrictions may apply. Patient must be enrolled in the program before use. See full Eligibility and Terms of Use at www.saphnelo.com or call Access 360 at 1-866-727-4635, Monday–Friday, 8 AM to 6 PM ET, excluding holidays.

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

APPROVED USE

SAPHNELO is a prescription medicine used to treat adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.

It is not known if SAPHNELO is effective in patients with severe active lupus nephritis or severe active central nervous system lupus. It is not known if SAPHNELO is safe and effective in patients under 18 years of age.

IMPORTANT SAFETY INFORMATION

- **Do not use SAPHNELO** if you are allergic to anifrolumab-fnia or to any of the ingredients
- **Before you receive SAPHNELO, tell your healthcare provider about all of your medical conditions, including if you:**
  - think you have an infection or have an infection that keeps coming back
  - are scheduled to receive a vaccination or if you think you may need a vaccination. You should not receive live vaccines during treatment with SAPHNELO
  - have or have had cancer
  - are receiving other biologic medicines or monoclonal antibodies
  - are pregnant or plan to become pregnant. It is not known if SAPHNELO will harm your unborn baby. Tell your healthcare provider if you are, might be, or plan to become pregnant during treatment with SAPHNELO
    - A pregnancy exposure registry monitors pregnancy outcomes in women exposed to SAPHNELO. You can find out more information about the registry by calling AstraZeneca at 1-877-693-9268
  - are breastfeeding or plan to breastfeed. It is not known if SAPHNELO passes into your breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works.

SAPHNELO may cause serious side effects, including:

- **Serious infections:** SAPHNELO can lower the ability of your immune system to fight infections. You may be at a higher risk of developing respiratory infections and shingles (herpes zoster) during treatment with SAPHNELO. Infections could be serious, leading to hospitalization or death
- **Allergic (hypersensitivity) reactions,** including anaphylaxis: Serious allergic reactions can happen during or after you get your SAPHNELO infusion. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of a serious allergic reaction:
  - swelling of your face, mouth and tongue
  - breathing problems
  - fainting, dizziness
  - feeling lightheaded (low blood pressure)
- **Cancer:** SAPHNELO may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers

The most common side effects of SAPHNELO include:
- Upper respiratory infections
- Bronchitis
- Infusion reactions
- Shingles (herpes zoster)
- Cough

Infusion reactions can happen at the time of the infusion or shortly after, symptoms may include headache, nausea, vomiting, feeling tired or weak (fatigue), and dizziness.

These are not all of the possible side effects of SAPHNELO. Call your healthcare provider for medical advice about side effects.

Please see full Prescribing Information, including Patient Information.

You may report side effects related to AstraZeneca products.

Saphnelo®
(anifrolumab-fnia)
Intravenous Use 300 mg/vial

Here for More.

Talk with your doctor today.

For more information, scan the QR code below with your smartphone to visit ***saphnelo.com***.

saphnelo.com

IMPORTANT SAFETY INFORMATION (cont'd)

SAPHNELO may cause serious side effects, including: (cont'd)

- **Cancer:** SAPHNELO may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers

The most common side effects of SAPHNELO include:

- Upper respiratory infections
- Bronchitis
- Infusion reactions
- Shingles (herpes zoster)
- Cough

Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.

SAPHNELO and SAPHNELO Supports are registered trademarks of the AstraZeneca group of companies.
©2023 AstraZeneca. All rights reserved.
US-68566 Last Updated 2/23